David J Brayden

List of Publications by Year
in descending order

151	6,856	53202 45	70222 77
papers	citations	h-index	g-index

155	155	155	7995
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intestinal permeation enhancers for oral peptide delivery. Advanced Drug Delivery Reviews, 2016, 106, 277-319.	14.3	275
2	Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia. European Journal of Pharmaceutical Sciences, 1998, 6, 153-163.	4.1	251
3	Expression of Specific Markers and Particle Transport in a New Human Intestinal M-Cell Model. Biochemical and Biophysical Research Communications, 2000, 279, 808-813.	2.2	249
4	Antibacterial Effects of Poly(2-(dimethylamino ethyl)methacrylate) against Selected Gram-Positive and Gram-Negative Bacteria. Biomacromolecules, 2010, 11, 443-453.	5.6	211
5	Keynote review: Intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discovery Today, 2005, 10, 1145-1157.	6.6	205
6	Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Advanced Drug Delivery Reviews, 2009, 61, 1427-1449.	14.3	199
7	<i>In Vitro</i> Models of the Intestinal Barrier. ATLA Alternatives To Laboratory Animals, 2001, 29, 649-668.	1.4	197
8	Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies. International Journal of Pharmaceutics, 2013, 440, 3-12.	5.4	155
9	Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10). Pharmaceutics, 2019, 11, 78.	4.6	149
10	Direct Peptide Bioconjugation/PEGylation at Tyrosine with Linear and Branched Polymeric Diazonium Salts. Journal of the American Chemical Society, 2012, 134, 7406-7413.	14.6	129
11	Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update. Pharmaceutics, 2019, 11, 41.	4.6	119
12	Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine, 2001, 20, 208-217.	4.0	117
13	Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine, 2001, 19, 1940-1950.	4.0	116
14	Phosphine-mediated one-pot thiolâ€“ene â€œclickâ€•approach to polymerâ€“protein conjugates. Chemical Communications, 2009, , 5272.	4.2	111
15	Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPETâ„¢. Expert Opinion on Drug Delivery, 2006, 3, 685-692.	5.1	110
16	Safety concerns over the use of intestinal permeation enhancers: A mini-review. Tissue Barriers, 2016, 4, e1176822.	3.2	104
17	Oral delivery strategies for nutraceuticals: Delivery vehicles and absorption enhancers. Trends in Food Science and Technology, 2016, 53, 90-101.	15.7	96
18	In Vitro and ex Vivo Intestinal Tissue Models to Measure Mucoadhesion of Poly (Methacrylate) and N-Trimethylated Chitosan Polymers. Pharmaceutical Research, 2005, 22, 38-49.	3.6	92

#	Article	IF	Citations
19	Controlled release technologies for drug delivery. Drug Discovery Today, 2003, 8, 976-978.	6.6	81
20	LabrasolÂ® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies. Journal of Controlled Release, 2019, 310, 115-126.	10.2	81
21	Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures. International Immunology, 2004, 16, 91-99.	4.0	79
22	Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol)) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 135, 51-59.	10.2	78
23	Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discovery Today: Technologies, 2012, 9, e113-e119.	4.2	78
24	Oral vaccination in man using antigens in particles: current status. European Journal of Pharmaceutical Sciences, 2001, 14, 183-189.	4.1	75
25	Buccal delivery of small molecules and biologics: of mucoadhesive polymers, films, and nanoparticles. Current Opinion in Pharmacology, 2017, 36, 22-28.	3.6	69
26	Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. Pharmaceutical Research, 1997, 14, 1772-1779.	3.6	68
27	Peptidoglycan recognition protein expression in mouse Peyerâ€™s Patch follicle associated epithelium suggests functional specialization. Cellular Immunology, 2003, 224, 8-16.	3.0	68
28	A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 830-839.	4.4	68
29	Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET^{Â®}). Therapeutic Delivery, 2011, 2, 1595-1610.	2.5	65
30	Myosin Light Chain Kinase Inhibition: Correction of Increased Intestinal Epithelial Permeability In Vitro. Pharmaceutical Research, 2008, 25, 1377-1386.	3.6	64
31	Microparticle vaccine approaches to stimulate mucosal immunisation. Microbes and Infection, 2001, 3, 867-876.	2.0	63
32	The role of citric acid in oral peptide and protein formulations: Relationship between calcium chelation and proteolysis inhibition. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 544-551.	4.4	63
33	An intra-articular salmon calcitonin-based nanocomplex reduces experimental inflammatory arthritis. Journal of Controlled Release, 2013, 167, 120-129.	10.2	61
34	Fluorescently tagged star polymers by living radical polymerisation for mucoadhesion and bioadhesion. Reactive and Functional Polymers, 2006, 66, 51-64.	4.3	59
35	Formulation Strategies to Improve Oral Peptide Delivery. Pharmaceutical Patent Analyst, 2014, 3, 313-336.	0.7	58
36	High content analysis of cytotoxic effects of pDMAEMA on human intestinal epithelial and monocyte cultures. Journal of Controlled Release, 2010, 146, 84-92.	10.2	54

#	Article	IF	Citations
37	Oral delivery of peptides: opportunities and issues for translation. Advanced Drug Delivery Reviews, 2016, 106, 193-195.	14.3	51
38	Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin. Journal of Controlled Release, 2018, 286, 402-414.	10.2	49
39	Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae. European Journal of Pharmaceutical Sciences, 2009, 38, 291-300.	4.1	48
40	Resistance of Staphylococcus aureus to the cationic antimicrobial agent poly(2-(dimethylamino) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 Medical Microbiology, 2011, 60, 968-976.	1.8	48
41	Evaluation of alkylmaltosides as intestinal permeation enhancers: Comparison between rat intestinal mucosal sheets and Caco-2 monolayers. European Journal of Pharmaceutical Sciences, 2012, 47, 701-712.	4.1	48
42	Non-antibiotic anti-diarrhoeal drugs: factors affecting oral bioavailability of berberine and loperamide in intestinal tissue. Advanced Drug Delivery Reviews, 1997, 23, 111-120.	14.3	47
43	Cracking the Junction: Update on the Progress of Gastrointestinal Absorption Enhancement in the Delivery of Poorly Absorbed Drugs. Critical Reviews in Therapeutic Drug Carrier Systems, 2008, 25, 117-168.	2.5	47
44	Dexamethasoneâ€“pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers. Journal of Controlled Release, 2009, 135, 35-43.	10.2	47
45	Formulation strategies to improve the efficacy of intestinal permeation enhancers,. Advanced Drug Delivery Reviews, 2021, 177, 113925.	14.3	47
46	Increased Intestinal Permeability in Rats Subjected to Traumatic Frontal Lobe Percussion Brain Injury. Journal of Trauma, 2008, 64, 131-138.	2.2	45
47	Restoration of Rat Colonic Epithelium After <i>In Situ</i> Intestinal Instillation of the Absorption promoter, Sodium Caprate. Therapeutic Delivery, 2010, 1, 75-82.	2.5	45
48	Transient Permeation EnhancerÂ® (TPEÂ®) technology for oral delivery of octreotide: a technological evaluation. Expert Opinion on Drug Delivery, 2021, 18, 1501-1512.	5.1	45
49	Apical membrane receptors on intestinal M cells: potential targets for vaccine delivery. Advanced Drug Delivery Reviews, 2004, 56, 721-726.	14.3	43
50	Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. Immunology Letters, 2005, 100, 182-188.	2.7	43
51	Progress in the delivery of nanoparticle constructs: towards clinical translation. Current Opinion in Pharmacology, 2014, 18, 120-128.	3.6	43
52	Redoxâ€Mediated Angiogenesis in the Hypoxic Joint of Inflammatory Arthritis. Arthritis and Rheumatology, 2014, 66, 3300-3310.	6.8	42
53	Evaluation of PepT1 transport of food-derived antihypertensive peptides, Ile-Pro-Pro and Leu-Lys-Pro using in vitro, ex vivo and in vivo transport models. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 115, 276-284.	4.4	42
54	A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10). European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 95-107.	4.4	42

#	Article	IF	Citations
55	High-content analysis for drug delivery and nanoparticle applications. Drug Discovery Today, 2015, 20, 942-957.	6.6	41
56	Effects of Lactobacillus salivarius 433118 on Intestinal Inflammation, Immunity Status and InÂvitro Colon Function in Two Mouse Models of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2008, 53, 2495-2506.	2.4	40
57	In vitro and in vivo characterisation of a novel peptide delivery system: Amphiphilic polyelectrolyteâ€“salmon calcitonin nanocomplexes. Journal of Controlled Release, 2010, 147, 289-297.	10.2	40
58	Sodium caprate-induced increases in intestinal permeability and epithelial damage are prevented by misoprostol. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 194-206.	4.4	40
59	Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans. Expert Opinion on Drug Delivery, 2021, 18, 273-300.	5.1	40
60	Evaluation of the Caco-2 monolayer as a model epithelium for iontophoretic transport. Pharmaceutical Research, 2000, 17, 1181-1188.	3.6	39
61	Effects of surfactant-based permeation enhancers on mannitol permeability, histology, and electrogenic ion transport responses in excised rat colonic mucosae. International Journal of Pharmaceutics, 2018, 539, 11-22.	5.4	39
62	Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. Veterinary Research Communications, 2008, 32, 93-106.	1.6	38
63	Evaluation of Sucrose Laurate as an Intestinal Permeation Enhancer for Macromolecules: Ex Vivo and In Vivo Studies. Pharmaceutics, 2019, 11, 565.	4.6	38
64	Stability, toxicity and intestinal permeation enhancement of two food-derived antihypertensive tripeptides, Ile-Pro-Pro and Leu-Lys-Pro. Peptides, 2015, 71, 1-7.	2.4	37
65	Nanoparticle passage through porcine jejunal mucus: Microfluidics and rheology. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 863-873.	3.5	36
66	Melittin as an Epithelial Permeability Enhancer I: Investigation of Its Mechanism of Action in Caco-2 Monolayers. Pharmaceutical Research, 2007, 24, 1336-1345.	3.6	35
67	Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines. Pharmaceutical Science & Technology Today, 1998, 1, 291-299.	0.9	33
68	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. European Journal of Pharmaceutical Sciences, 2022, 170, 106098.	4.1	33
69	Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies. European Journal of Pharmaceutical Sciences, 2009, 38, 301-311.	4.1	32
70	Melittin as a Permeability Enhancer II: In Vitro Investigations in Human Mucus Secreting Intestinal Monolayers and Rat Colonic Mucosae. Pharmaceutical Research, 2007, 24, 1346-1356.	3.6	31
71	Oral Peptide Delivery: Prioritizing the Leading Technologies. Therapeutic Delivery, 2011, 2, 1567-1573.	2.5	29
72	Investigation of coco-glucoside as a novel intestinal permeation enhancer in rat models. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 856-865.	4.4	29

#	Article	IF	Citations
73	Efficacious Intestinal Permeation Enhancement Induced by the Sodium Salt of 10-undecylenic Acid, A Medium Chain Fatty Acid Derivative. AAPS Journal, 2014, 16, 1064-1076.	4.7	29
74	Silica-Coated Nanoparticles with a Core of Zinc, <scp>l</scp>-Arginine, and a Peptide Designed for Oral Delivery. ACS Applied Materials & Interfaces, 2020, 12, 1257-1269.	8.3	29
75	Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers. European Journal of Pharmaceutical Sciences, 2020, 154, 105509.	4.1	28
76	Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin. International Journal of Pharmaceutics, 2010, 387, 154-160.	5.4	27
77	Site-specific N-terminus conjugation of poly(mPEG1100) methacrylates to salmon calcitonin: synthesis and preliminary biological evaluation. Soft Matter, 2009, 5, 3038.	2.8	26
78	Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C10): Isolated rat intestinal mucosae and sacs. European Journal of Pharmaceutical Sciences, 2021, 158, 105685.	4.1	26
79	High content analysis to determine cytotoxicity of the antimicrobial peptide, melittin and selected structural analogs. Peptides, 2011, 32, 1764-1773.	2.4	25
80	PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights. Journal of Controlled Release, 2011, 149, 126-132.	10.2	25
81	A comparison of three Peyerâ€™s patch â€œM-likeâ€•cell culture models: particle uptake, bacterial interaction, and epithelial histology. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 426-436.	4.4	25
82	Sodium caprate enables the blood pressure-lowering effect of Ile-Pro-Pro and Leu-Lys-Pro in spontaneously hypertensive rats by indirectly overcoming PepT1 inhibition. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 128, 179-187.	4.4	24
83	Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer. European Journal of Pharmaceutical Sciences, 2013, 48, 726-734.	4.1	23
84	In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPillÂ®) of salmon calcitonin. European Journal of Pharmaceutical Sciences, 2015, 79, 102-111.	4.1	23
85	Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered Î²-amyloid in mice. Vaccine, 2001, 19, 4185-4193.	4.0	22
86	Growth and characterisation of a cell culture model of the feline bloodâ€“brain barrier. Veterinary Immunology and Immunopathology, 2006, 109, 233-244.	1.2	22
87	In vitro Interactions Between the Oral Absorption Promoter, Sodium Caprate (C10) and S. typhimurium in Rat Intestinal Ileal Mucosae. Pharmaceutical Research, 2008, 25, 114-122.	3.6	22
88	Rat, ovine and bovine Peyer's patches mounted in horizontal diffusion chambers display sampling function. Journal of Controlled Release, 2006, 115, 68-77.	10.2	21
89	First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models. Neuropharmacology, 2015, 89, 193-203.	4.2	19
90	Amphiphilic Star Polypept(o)ides as Nanomeric Vectors in Mucosal Drug Delivery. Biomacromolecules, 2020, 21, 2455-2462.	5.6	19

#	Article	IF	Citations
91	Drug Delivery Systems in Domestic Animal Species. Handbook of Experimental Pharmacology, 2010, , 79-112.	0.0	18
92	LabrasolÂ® and Salts of Medium-Chain Fatty Acids Can Be Combined in Low Concentrations to Increase the Permeability of a Macromolecule Marker Across Isolated Rat Intestinal Mucosae. Journal of Pharmaceutical Sciences, 2018, 107, 1648-1655.	3.3	18
93	An Enteric-Coated Polyelectrolyte Nanocomplex Delivers Insulin in Rat Intestinal Instillations When Combined with a Permeation Enhancer. Pharmaceutics, 2020, 12, 259.	4.6	18
94	Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage. Journal of Controlled Release, 2016, 238, 242-252.	10.2	17
95	Sodium glycodeoxycholate and sodium deoxycholate as epithelial permeation enhancers: in vitro and ex vivo intestinal and buccal bioassays. European Journal of Pharmaceutical Sciences, 2021, 159, 105737.	4.1	17
96	Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. Acta Biomaterialia, 2022, 140, 561-572.	8.8	17
97	Cultured human sweat gland epithelia: isolation of glands using neutral red. Pharmaceutical Research, 1995, 12, 171-175.	3.6	16
98	A Tertiary Amino-Containing Polymethacrylate Polymer Protects Mucus-Covered Intestinal Epithelial Monolayers Against Pathogenic Challenge. Pharmaceutical Research, 2008, 25, 1193-1201.	3.6	16
99	Mechanisms of action of zinc on rat intestinal epithelial electrogenic ion secretion: insights into its antidiarrhoeal actions. Journal of Pharmacy and Pharmacology, 2012, 64, 644-653.	2.6	16
100	Controlled Release Drug Delivery in Farmed Animals: Commercial Challenges and Academic Opportunities. Current Drug Delivery, 2009, 6, 383-390.	1.7	15
101	Zinc sulphate attenuates chloride secretion in Human colonic mucosae in vitro. European Journal of Pharmacology, 2012, 696, 166-171.	3.6	14
102	Transepithelial Transport of PAMAM Dendrimers across Isolated Rat Jejunal Mucosae in Ussing Chambers. Biomacromolecules, 2014, 15, 2889-2895.	5.6	14
103	Progress in the Formulation and Delivery of Somatostatin Analogs for Acromegaly. Therapeutic Delivery, 2017, 8, 867-878.	2.5	14
104	Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. Drug Delivery and Translational Research, 2018, 8, 1421-1435.	6.0	14
105	The Centenary of the Discovery of Insulin: An Update on the Quest for Oral Delivery. Frontiers in Drug Delivery, 2021, 1, .	1.7	14
106	Iontophoresis-enhanced absorptive flux of polar molecules across intestinal tissue in vitro. Pharmaceutical Research, 2000, 17, 476-478.	3.6	13
107	Development of Nanotoxicology: Implications for Drug Delivery and Medical Devices. Nanomedicine, 2015, 10, 2289-2305.	3.5	13
108	TNFÎ±-dependent anhedonia and upregulation of hippocampal serotonin transporter activity in a mouse model of collagen-induced arthritis. Neuropharmacology, 2018, 137, 211-220.	4.2	12

#	Article	IF	Citations
109	Formulation, Characterisation and Evaluation of the Antihypertensive Peptides, Isoleucine-Proline-Proline and Leucine-Lysine-Proline in Chitosan Nanoparticles Coated with Zein for Oral Drug Delivery. International Journal of Molecular Sciences, 2022, 23, 11160.	4.2	12
110	Catching target receptors for drug and vaccine delivery using TOGAÂ® gene expression profiling. Advanced Drug Delivery Reviews, 2002, 54, 1213-1223.	14.3	11
111	Feline immunodeficiency virus infection: A valuable model to study HIV-1 associated encephalitis. Veterinary Immunology and Immunopathology, 2008, 123, 134-137.	1.2	11
112	Translocation of<i>Vibrio parahaemolyticus</i>across an<i>in vitro</i>M cell model. FEMS Microbiology Letters, 2014, 350, 65-71.	1.8	11
113	Measuring the oral bioavailability of protein hydrolysates derived from food sources: A critical review of current bioassays. Biomedicine and Pharmacotherapy, 2021, 144, 112275.	5.8	11
114	Barriers to the Intestinal Absorption of Four Insulin-Loaded Arginine-Rich Nanoparticles in Human and Rat. ACS Nano, 2022, 16, 14210-14229.	15.3	11
115	Poly(Ethylene Glycol)-Based Backbones with High Peptide Loading Capacities. Molecules, 2014, 19, 17559-17577.	3.9	9
116	Track Analysis of the Passage of rhodamine-labeled Liposomes Across Porcine Jejunal Mucus in a Microchannel Device. Therapeutic Delivery, 2018, 9, 419-433.	2.5	9
117	Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients. Expert Opinion on Drug Discovery, 2021, 16, 235-254.	5.1	9
118	Permeability-enhancing effects of three laurate-disaccharide monoesters across isolated rat intestinal mucosae. International Journal of Pharmaceutics, 2021, 601, 120593.	5.4	9
119	Oral Absorption Enhancement: Taking the Next Steps in Therapeutic Delivery. Therapeutic Delivery, 2010, 1, 5-9.	2.5	8
120	Stomaching Drug Delivery. New England Journal of Medicine, 2019, 380, 1671-1673.	30.1	7
121	Evolving peptides for oral intake. Nature Biomedical Engineering, 2020, 4, 487-488.	22.4	7
122	Add Sugar to Chitosan: Mucoadhesion and In Vitro Intestinal Permeability of Mannosylated Chitosan Nanocarriers. Pharmaceutics, 2022, 14, 830.	4.6	7
123	Oral Delivery of Pathogens from the Intestine to the Nervous System. Journal of Drug Targeting, 2004, 12, 71-78.	4.5	6
124	Opportunities for drug-delivery Research in Nutraceuticals and Functional foods?. Therapeutic Delivery, 2013, 4, 301-305.	2.5	6
125	Development of a Non-Aqueous Dispersion to Improve Intestinal Epithelial Flux of Poorly Permeable Macromolecules. AAPS Journal, 2017, 19, 244-253.	4.7	6
126	Synthesis and In Vivo Evaluation of Insulin-Loaded Whey Beads as an Oral Peptide Delivery System. Pharmaceutics, 2021, 13, 656.	4.6	4

#	Article	IF	Citations
127	Nanostructures Overcoming the Intestinal Barrier: Physiological Considerations and Mechanistic Issues. , 2012, , 39-62.		4
128	A novel in vitro electrophysiological bioassay for transport of loperamide across intestinal epithelia. Pharmaceutical Research, 1997, 14, 942-945.	3.6	3
129	Introduction for the special issue on recent advances in drug delivery across tissue barriers. Tissue Barriers, 2016, 4, e1187981.	3.2	3
130	Effect of Overencapsulation on the Disintegration and Dissolution of Licensed Formulations for Blinding in Randomized Controlled Trials. Journal of Pharmaceutical Sciences, 2019, 108, 1227-1235.	3.3	3
131	NANOSTRUCTURES OVERCOMING THE INTESTINAL BARRIER: DRUG DELIVERY STRATEGIES. , 2012, , 63-90.		3
132	Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials. BioDrugs, 2022, 36, 687-700.	5.0	3
133	Per Arturssonâ€™s Major Contributions to the Caco-2ÂCell Literature in Pharmaceutical Sciences. Journal of Pharmaceutical Sciences, 2021, 110, 12-16.	3.3	2
134	Protein kinase D, ubiquitin and proteasome pathways are involved in adenosine receptor-stimulated NR4A expression in myeloid cells. Biochemical and Biophysical Research Communications, 2021, 555, 19-25.	2.2	2
135	Entrapment of Hydrophilic and Hydrophobic Molecules in Beads Prepared from Isolated Denatured Whey Protein. Pharmaceutics, 2021, 13, 1001.	4.6	2
136	A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development. AAPS Journal, 2022, 24, 61.	4.7	2
137	Fast-track approaches to selecting discovery candidates for full development. Drug Discovery Today, 1998, 3, 6-7.	6.6	0
138	In vitro inhibition of cytochalasin induced tight junction opening in human colon. Gastroenterology, 2003, 124, A316.	1.4	0
139	Pathogen invasion across intestine: mechanisms and potential exploitation. Advanced Drug Delivery Reviews, 2004, 56, 717-719.	14.3	0
140	New technologiesPharmacology applied: delivering the goods. Current Opinion in Pharmacology, 2006, 6, 491-493.	3.6	0
141	Conference Report: the 2nd Annual Irish Drug Delivery Network Conference With UK and Ireland Controlled Release Society: Advancing Drug Delivery. Therapeutic Delivery, 2010, 1, 505-509.	2.5	0
142	Human: Veterinary Technology Cross Over. Advances in Delivery Science and Technology, 2013, , 359-375.	0.0	0
143	The Challenges and Future of Oral Drug Delivery: An Interview with David Brayden. Therapeutic Delivery, 2016, 7, 791-794.	2.5	0
144	Hepatic gateways. Expert Review of Gastroenterology and Hepatology, 2016, 10, 561-563.	3.0	0

#	Article	IF	Citations
145	Editorial overview: New technologies: drug delivery and medical devices combinations, more than the sum of the parts. Current Opinion in Pharmacology, 2017, 36, iv-vii.	3.6	0
146	AB069. NR4A1 agonist CsnB may affect macrophage cells primarily within colorectal tumours in order to reduce pro-inflammatory response. Mesentery and Peritoneum, 0, 4, AB069-AB069.	0.1	0
147	AB073. Attenuation of pathogenic pro-inflammatory signals in colorectal cancer via an NR4A1 agonist cytosporone B. Mesentery and Peritoneum, 0, 4, AB073-AB073.	0.1	0
148	Drug Delivery Formulations and Devices Tailored for Paediatric and Older Patients. Frontiers in Drug Delivery, 2021, 1, .	1.7	0
149	Evaluation of Selenomethionine Entrapped in Nanoparticles for Oral Supplementation Using In Vitro, Ex Vivo and In Vivo Models. Molecules, 2023, 28, 2941.	3.9	0
150	Reproducible Synthesis of Biocompatible Albumin Nanoparticles Designed for Intra-articular Administration of Celecoxib to Treat Osteoarthritis. ACS Applied Materials & Interfaces, 2024, 16, 14633-14644.	8.3	0
151	LabrafacTM MC60 is an efficacious intestinal permeation enhancer for macromolecules: Comparisons with LabrasolÂ® ALF in ex vivo and in vivo rat studies. International Journal of Pharmaceutics, 2024, 661, 124353.	5.4	0